Aug 17, 2026 06:51AM
Aug 14, 2026 08:30AM
Aug 10, 2026 08:01AM
Aug 10, 2026 08:00AM
Jun 22, 2026 08:30AM
May 14, 2026 08:00AM
May 4, 2026 08:01AM Clene plans accelerated FDA filing for ALS drug CNM-Au8 in Q3 2026
May 4, 2026 08:00AM
Mar 12, 2026 08:00AM
Feb 24, 2026 08:00AM
Jan 12, 2026 08:31AM
Jan 12, 2026 08:30AM
Jan 9, 2026 08:30AM
Jan 9, 2026 08:30AM Clene Announces Registered Direct Offering of Over $28 Million
Dec 4, 2025 08:42AM
Dec 3, 2025 08:01AM
Dec 3, 2025 08:00AM
Nov 20, 2025 09:11AM
Nov 13, 2025 08:00AM
Sep 26, 2025 08:50AM
Sep 25, 2025 08:00AM Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Sep 10, 2025 08:52AM
Sep 4, 2025 08:30AM
Aug 18, 2025 06:41AM
Aug 14, 2025 08:38AM
Jul 1, 2025 09:29AM
Jul 1, 2025 06:53AM
Jun 30, 2025 08:05AM Clene (CLNN) Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
Jun 30, 2025 08:00AM
May 7, 2025 08:00AM
Mar 25, 2025 06:50AM
Mar 24, 2025 08:00AM
Mar 13, 2025 06:48AM
Mar 12, 2025 08:02AM
Mar 12, 2025 08:00AM Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
Feb 26, 2025 06:50AM
Feb 25, 2025 08:03AM
Feb 25, 2025 08:00AM
Dec 19, 2024 08:00AM
Dec 10, 2024 08:30AM
Nov 22, 2024 06:55AM
Nov 14, 2024 07:11AM Clene, Inc. (CLNN) PT Lowered to $83 at Canaccord Genuity
Nov 13, 2024 08:00AM
Oct 10, 2024 06:18AM
Oct 4, 2024 06:46AM
Oct 1, 2024 04:00PM
Sep 17, 2024 06:57AM
Sep 16, 2024 08:32AM
Sep 16, 2024 08:30AM Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
Aug 8, 2024 08:00AM

330,175 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All